How to overcome sceptism over biosimilars

Biosimilars are facing the same sort of doctor and patient scepticism that generics met when they were first introduced – and the name’s not helping.

But, says Generic and Biosimilar Medicines Association CEO Belinda Wood, the commercial advantage with biosimilars for retail pharmacy is the same as in stocking generics – with massive savings for the health system to boot.

Because they’re called biosimiliars, she says the name suggests they are not identical to biologics and won